Tufts Says Weak Outcomes Data, Payor Diffidence on MDx Have Slowed the Growth of Personalized Medicine
July 20, 2011
Tufts Says Weak Outcomes Data, Payor Diffidence on MDx Have Slowed the Growth of Personalized Medicine
The study concluded that a lack of evidence linking diagnostic tests to clinical outcomes has made payors skeptical, hindering the growth of personalized medicine.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Diaceutics Report Sheds Doubt on Pharmas' Personalized Medicine Preparedness
June 15, 2011 / Pharmacogenomics Reporter - Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - Study Shows Genes Associated with Nicotine Dependence Also Predict Response to Anti-Smoking Therapy
June 13, 2012 / Pharmacogenomics Reporter - Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter - Q&A: Diaceutics CEO Keeling Provides Personalized Rx-Focused Consultant's View of Industry Progress
February 22, 2012 / Pharmacogenomics Reporter